214 related articles for article (PubMed ID: 35980134)
21. Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features.
Soliman DS; Al-Kuwari E; Siveen KS; Al-Abdulla R; Chandra P; Yassin M; Nashwan A; Hilmi FA; Taha RY; Nawaz Z; El-Omri H; Mateo JM; Al-Sabbagh A
Int J Lab Hematol; 2021 Jun; 43(3):515-525. PubMed ID: 33314668
[TBL] [Abstract][Full Text] [Related]
22. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
23. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
24. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry.
Cabezudo E; Matutes E; Ramrattan M; Morilla R; Catovsky D
Leukemia; 1997 Nov; 11(11):1909-14. PubMed ID: 9369425
[TBL] [Abstract][Full Text] [Related]
25. Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.
Jovanovic D; Djurdjevic P; Andjelkovic N; Zivic L
Contemp Oncol (Pozn); 2014; 18(1):29-33. PubMed ID: 24876818
[TBL] [Abstract][Full Text] [Related]
26. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma.
Kilo MN; Dorfman DM
Am J Clin Pathol; 1996 Apr; 105(4):451-7. PubMed ID: 8604687
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
Asaad NY; Abd El-Wahed MM; Dawoud MM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
[TBL] [Abstract][Full Text] [Related]
28. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
29. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Siddiqi T; Soumerai JD; Dorritie KA; Stephens DM; Riedell PA; Arnason J; Kipps TJ; Gillenwater HH; Gong L; Yang L; Ogasawara K; Thorpe J; Wierda WG
Blood; 2022 Mar; 139(12):1794-1806. PubMed ID: 34699592
[TBL] [Abstract][Full Text] [Related]
32. CD23 expression in transformed small lymphocytic lymphomas/chronic lymphocytic leukemias and blastic transformations of mantle cell lymphoma.
Dunphy CH; Wheaton SE; Perkins SL
Mod Pathol; 1997 Aug; 10(8):818-22. PubMed ID: 9267825
[TBL] [Abstract][Full Text] [Related]
33. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
[TBL] [Abstract][Full Text] [Related]
34. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.
Rawstron AC; Kennedy B; Evans PA; Davies FE; Richards SJ; Haynes AP; Russell NH; Hale G; Morgan GJ; Jack AS; Hillmen P
Blood; 2001 Jul; 98(1):29-35. PubMed ID: 11418459
[TBL] [Abstract][Full Text] [Related]
35. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
36. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
D'Arena G; Sgambato A; Volpe S; Coppola G; Amodeo R; Tirino V; D'Auria F; Statuto T; Valvano L; Pietrantuono G; Deaglio S; Efremov D; Laurenti L; Aiello A
Hematol Oncol; 2022 Dec; 40(5):835-842. PubMed ID: 35667043
[TBL] [Abstract][Full Text] [Related]
38. [Pathologic characteristics of bone marrow for
CD5 positive small B cell lymphoma].
Peng S; Zhu F; You S; Gong M; Wen Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Apr; 41(4):374-9. PubMed ID: 27241147
[TBL] [Abstract][Full Text] [Related]
39. Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.
Czader M; Amador C; Cook JR; Thakkar D; Parker C; Dave SS; Dogan A; Duffield AS; Nejati R; Ott G; Xiao W; Wasik M; Goodlad JR
Am J Clin Pathol; 2023 Jun; 159(6):554-571. PubMed ID: 37052539
[TBL] [Abstract][Full Text] [Related]
40. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
Blix ES; Irish JM; Husebekk A; Delabie J; Forfang L; Tierens AM; Myklebust JH; Kolstad A
BMC Cancer; 2012 Oct; 12():478. PubMed ID: 23072591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
